Myelofibrosis malady

NIH Rare Diseases: Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by fibrous (scar) tissue. Scarring of the bone marrow causes anemia, which can lead to fatigue and weakness, as well as pooling of the blood in abnormal sites like the liver and spleen, causing these organs to swell. Although myelofibrosis can occur at any age, it typically develops after the age of 50. In most cases, myelofibrosis gets progressively worse. Treatment is aimed at relieving signs and symptoms and may include medications, blood transfusions, chemotherapy, radiation therapy and surgery.   ³⁰

MalaCards: Myelofibrosis, also known as primary myelofibrosis, is related to essential thrombocythemia and polycythemia vera. An important gene associated with Myelofibrosis is JAK2 (Janus kinase 2), and among its related pathways are Actin-Based Motility by Rho Family GTPases and Ras Pathway. The drug busulfan and the compounds cyclophosphamide and threonine have been mentioned in the context of this disorder. Affiliated tissues include the bone marrow which results_in bone marrow being replaced by fibrous (scar) tissue, bone marrow and whole blood, and related mouse phenotypes are respiratory system and craniofacial.

Disease Ontology: A myeloma that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue.⁶

Genetics Home Reference: Primary myelofibrosis is a condition characterized by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis.¹⁷

Wikipedia: Myelofibrosis, also known as myeloid metaplasia, chronic idiopathic myelofibrosis, osteomyelofibrosis...⁴⁴ more...

OMIM: 254450

Aliases & Descriptions:

myelofibrosis 6 7 30 8 32 43 primary myelofibrosis 6 30 17 32 43 myeloid metaplasia 30 17 8 32 43 agnogenic myeloid metaplasia 6 30 17 32 idiopathic myelofibrosis 30 17 32 chronic idiopathic myelofibrosis 6 17 megakaryocytic myelosclerosis 6 43 myelofibrosis with myeloid metaplasia 17

idiopathic bone marrow fibrosis 6 myelofibrosis, idiopathic 33 myelofibrosis (disorder) 6 bone marrow fibrosis 6 myelosclerosis, nos 6 aleukemic myelosis 6 myelosclerosis 6

Diseases related to myelofibrosis by text searches and GeneDecks gene sharing:

(show top 50)    (show all 829)

id	Related Disease	Score	Top Affiliating Genes
1	essential thrombocythemia	34.5	MPL, JAK2, THPO
2	polycythemia vera	30.4	KIT, KITLG, RARB, BCR, MPL, MPO
3	hemolytic anemia	29.7	MPO, CD40LG, IL3, IFNA1, IFNA2, IFNG
4	pure red-cell aplasia	29.7	KITLG, CD79A, CD40LG, IL3, IFNA1, TIMP1
5	osteosclerosis	29.7	VEGFA, BMP2, CD40LG, IL11, IFNA2, TNFRSF11B
6	polycythemia	29.4	KIT, KITLG, VEGFA, RARB, BCR, MPL
7	splenomegaly	28.7	VEGFA, MPL, JAK2, IFNA1, IFNA2, TET2
8	hairy cell leukemia	28.3	FLT3, IL3, IFNA1, IFNA2, PTPRC, ACP5
9	paroxysmal nocturnal hemoglobinuria	28.1	CEACAM8, HMGA2, PLAUR, WT1, CSF3, EPO
10	hemoglobinuria	28.0	CEACAM8, HMGA2, PLAUR, WT1, CSF3, EPO
11	t-cell leukemia	28.0	MYB, IL3, PTPRC, STAT3, STAT5A, LYN
12	erythrocytosis	27.9	SH2B3, KITLG, MPL, JAK2, CD177, IL11
13	mastocytosis	27.9	KIT, KITLG, MPO, JAK2, FIP1L1, FGFR1
14	acute megakaryoblastic leukemia	27.9	MPO, IL11, IL3, PF4, THPO, RUNX1
15	acute myeloid leukemia	27.7	KIT, FLT3, NPM1, RUNX1
16	chronic myeloproliferative disease	27.6	VEGFA, MPL, MPO, JAK2, CD177, FLT3
17	uremia	27.6	ITGAM, IFNG, F8, TP53, TNF, TNFRSF11B
18	stem cell leukemia	27.4	KIT, ZMYM2, MPO, FLT3, FGFR1, KRT7
19	aplastic anemia	27.4	KITLG, MPL, CD34, FLT3, IL11, IL3
20	myeloproliferative disorder	27.3	KIT, KITLG, ZMYM2, KDR, BCR, MPL
21	megakaryoblastic leukemia	27.1	KIT, KITLG, BMP6, ZFPM1, MPL, MPO
22	thrombocytosis	26.9	KITLG, VEGFA, LIF, MPL, JAK1, JAK2
23	chronic myeloid leukemia	26.6	KIT, KITLG, MYB, BCR, CEACAM8, MPL
24	was-related disorders	26.5	MPO, IL8, IDH1, IDH2, TNFSF11, WT1
25	chronic myelomonocytic leukemia	26.4	MPO, JAK2, ASXL1, FLT3, IL3, EZH2
26	peripheral t-cell lymphoma	26.3	BMP6, JAK2, FGF2, IL15, IFNG, ETV6
27	wilms tumor	25.2	VEGFA, MYB, BMP6, FLT3, FGF2, IFNA2
28	pulmonary hypertension	24.7	VEGFA, BMP2, BMP6, BMP7, BMPR1B, KDR
29	thrombosis	24.5	VEGFA, MPL, MPO, JAK2, CD79A, CD40LG
30	myelomonocytic leukemia	23.7	MYB, MPO, JAK2, ASXL1, FLT3, IL3
31	myelodysplastic syndrome	23.2	KIT, KITLG, VEGFA, MYB, BMP6, KDR
32	hematopoiesis	22.4	SH2B3, KIT, KITLG, VEGFA, MYB, BMP6
33	thrombocytopenia	22.0	KITLG, MYB, BMP6, ZFPM1, MPL, CD79A
34	hypertension	20.3	SH2B3, KIT, VEGFA, BMP2, BMP6, BMP7
35	anemia	20.0	KIT, KITLG, VEGFA, BNIP3, MYB, BMP2
36	tuberculosis	19.9	VEGFA, BMP6, JAK1, JAK2, CD79A, CD40LG
37	peritonitis	18.5	KIT, KITLG, VEGFA, BNIP3, BMP6, BMP7
38	fibrosis	18.2	KIT, KITLG, VEGFA, BMP1, BMP2, BMP6
39	leukemia	16.2	SH2B3, KIT, KITLG, VEGFA, BNIP3, MYB
40	sarcoma	15.3	KIT, KITLG, VEGFA, BMP1, BMP2, BMP6
41	myeloid leukemia	14.8	KIT, KITLG, VEGFA, BNIP3, MYB, BMP6
42	ovarian cancer	14.5	KIT, KITLG, VEGFA, BMP1, BMP2, BMP6
43	hemorrhagic thrombocythemia	14.1	MPL, JAK2, CD177, THPO
44	portal vein thrombosis	14.1	JAK2, IFNA1, IFNA2, F8, THPO, EPO
45	autoimmune thrombocytopenic purpura	14.1	MPL, IL11, PF4, THPO
46	congenital amegakaryocytic thrombocytopenia	14.0	MPL, IL3, THPO
47	hypersplenism	14.0	IL11, THPO, CSF3, EPO
48	bone marrow cancer	14.0	KIT, ZMYM2, FLT3, IL3
49	primary polycythemia	14.0	JAK2, STAT5A, EPO
50	thrombocytopenia, x-linked	14.0	ZFPM1, THPO, GATA1

Clinical features from OMIM: 254450

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 busulfan

MalaCards organs/tissues related to myelofibrosis:

²²

FMA organs/tissues related to myelofibrosis:

¹¹

MGI Mouse Phenotypes related to myelofibrosis:

²⁵ (show all 28)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	10.5	FEN1, PTPRC, NOG, STAT5B, PRG2, GATA1
2	craniofacial phenotype	MP:0005382	9.4	KIT, KITLG, BMP1, BMPR1B, MKS1, HMGA2
3	other phenotype	MP:0005395	9.1	STAT3, PDGFRA, FN1, MMP14, CD40LG, JAK2
4	endocrine/exocrine gland phenotype	MP:0005379	9.1	BMPR1B, CD40LG, FGFR1, IFNG, ETV6, HMGA2
5	hearing/vestibular/ear phenotype	MP:0005377	9.0	FGFR1, HMGA2, TNFRSF11B, NOG, CSF1R, FGF2
6	embryogenesis phenotype	MP:0005380	8.3	FGFR1, FEN1, EZH2, ETV6, NOG, PDGFRA
7	adipose tissue phenotype	MP:0005375	8.3	STAT5B, STAT5A, STAT3, TGFBR2, TGFB1, PDGFRB
8	renal/urinary system phenotype	MP:0005367	8.3	KIT, BMP7, RARB, BCR, MMP14, MKS1
9	no phenotypic analysis	MP:0003012	8.2	RUNX1, PML, TET2, TP53, ETV6, EZH2
10	hematopoietic system phenotype	MP:0005397	8.2	EPO, EPX, GATA1, ENG, EZH2, ETV6
11	liver/biliary system phenotype	MP:0005370	8.1	NPM1, RUNX1, LYN, EPO, GATA1, SOCS3
12	limbs/digits/tail phenotype	MP:0005371	8.0	HMGA2, TNFRSF11B, TNFSF11, PTH, NOG, PDGFRA
13	behavior/neurological phenotype	MP:0005386	7.8	PLAUR, PDGFRA, TIMP2, TGFBR2, STAT5A, STAT5B
14	nervous system phenotype	MP:0003631	7.7	TGFB1, THBD, TIMP2, PDGFRA, NOG, DNMT3A
15	integument phenotype	MP:0010771	7.4	CSF1R, CSF3, NPM1, RUNX1, GATA1, SOCS3
16	skeleton phenotype	MP:0005390	6.7	MMP14, FN1, MKS1, FGF2, FGFR1, TP53
17	reproductive system phenotype	MP:0005389	6.5	MMP14, FN1, MKS1, FGF2, IL15, IFNG
18	digestive/alimentary phenotype	MP:0005381	6.4	EP300, LYN, SOCS3, CXCR4, TGFBR2, TGFB1
19	tumorigenesis	MP:0002006	6.3	TP53, TNF, TET2, PTPRC, PDGFRA, TIMP1
20	normal phenotype	MP:0002873	6.0	EZH2, ETV6, TET2, PTPRC, NOG, PDGFRA
21	vision/eye phenotype	MP:0005391	5.7	TP53, TNF, NOG, PDGFRB, THBS1, TGFB1
22	growth/size phenotype	MP:0005378	4.5	TP53, STAT5B, CXCR2, SOCS3, CSF1R, NPM1
23	muscle phenotype	MP:0005369	4.4	AHSG, WT1, PDGFRB, PDGFRA, NOG, PLAUR
24	immune system phenotype	MP:0005387	4.4	KIT, F8, EZH2, ETV6, TP53, TNF
25	homeostasis/metabolism phenotype	MP:0005376	4.1	DNMT3A, STAT3, STAT5A, STAT5B, CXCR2, CXCR4
26	mortality/aging	MP:0010768	3.7	MKS1, FLT3, FKBP5, FEN1, IL15, ENG
27	cardiovascular system phenotype	MP:0005385	2.6	BMP2, BMP7, RARB, LIF, ZFPM1, KDR
28	cellular phenotype	MP:0005384	1.6	KITLG, VEGFA, BNIP3, MYB, BMP2, BMP8B

Articles related to myelofibrosis:

(show top 50)    (show all 199)

id	Title	Authors	Year	Affiliating Genes
1	MPL immunohistochemical expression as a novel marker for essential thrombocythemia and primary myelofibrosis differential diagnosis. (21752469)	Ponce C.C.... Silva M.R.	2012	PML
2	The JAK2V617F allele burden and STAT3- and STAT5 phos phorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis co mpared with essential thrombocythemia, polycythemia vera and myelofibrosis. (21749449)	Risum M.... Hasselbalch H.C.	2011	JAK2, STAT3, STAT5A
3	JAK2(V617F) allele burden in polycythemia vera correl ates with grade of myelofibrosis, but is not substantially affected by therapy. (20650526)	Silver R.T.... Cross N.C.	2010	JAK2
4	Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. (20520633)	Guglielmelli P.... Vannucchi A.M.	2010	JAK2, MPL
5	Bone marrow mesenchymal stromal cells remain of recip ient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in pa tients with myelofibrosis. (19629639)	Bacher U.... Ayuk F.	2010	JAK2
6	Identification of MPL W515L/K mutations in patients w ith primary myelofibrosis and essential thrombocythaemia by allele-specific pol ymerase chain reaction. (19521067)	Daly S.... Langabeer S.E.	2009	JAK2, MPL
7	Peripheral T-cell lymphoma presenting as myelofibrosi s with the expression of basic fibroblast growth factor. (20002760)	Kikukawa M.... Iwamoto T.	2009	FGF2
8	Postpolycythaemic myelofibrosis: frequency and risk f actors for this complication in 116 patients. (19604233)	Alvarez-LarrA!n A.... Besses C.	2009	JAK2
9	SOCS3 inhibits TPO-stimulated, but not spontaneous, m egakaryocytic growth in primary myelofibrosis. (19225535)	ChalignAc R.... Giraudier S.	2009	TPO, SOCS3
10	Identification of patients with poorer survival in pr imary myelofibrosis based on the burden of JAK2V617F mutated allele. (19549988)	Guglielmelli P.... Vannucchi A.M.	2009	JAK2
11	Elevated TNF-alpha and LDH without parathormone disturbance is associated with diffuse osteolytic lesions in leukemic transformation of myelofibrosis. (17976926)	Jurisic V.... Colovic M.	2008	TNF, PTH
12	Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. (18429051)	Tefferi A.	2008	JAK2
13	Decreased JAK2 V617F allele burden level in a myelofibrosis with myeloid metaplasia patient with leukemic transformation. (18455791)	Wu Y.Y.... Ho C.L.	2008	JAK2
14	New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. (18528423)	Chaligne R.... Giraudier S.	2008	MPL
15	Clinical correlates of serum pro-major basic protein in a spectrum of eosinophilic disorders and myelofibrosis. (19039208)	Ho C.L.... Tefferi A.	2008	PRG2
16	Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. (17408465)	Guglielmelli P.... .	2007	MPL
17	Haematopoietic cell lineage distribution of MPLW515L/K mutations in patients with idiopathic myelofibrosis. (17408398)	Hu W.Y.... Xu M.	2007	MPL
18	The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. (17350297)	Rosti V.... .	2007	CXCR4
19	Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia. (17133423)	Ruiz-ArgA1elles G.J.... Camoriano J.K.	2007	JAK2
20	The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. (17961178)	Larsen T.S.... Hasselbalch H.C.	2007	JAK2
21	B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. (17296581)	Bogani C.... Vannucchi A.M.	2007	JAK2
22	Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis. (17889703)	Andrieux J.... Vandenberghe P.	2007	BMPR1B, BMP2, NOG
23	Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. (17476275)	Bornhauser M.... Thiede C.	2007	JAK2
24	Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. (17107350)	Lasho T.L.... Tefferi A.	2006	MPL
25	More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders. (16461764)	Steensma D.P.... Roberts A.W.	2006	MYB, EP300
26	Expression of HMGA2 in PB leukocytes and purified CD34+ cells from controls and patients with Myelofibrosis and myeloid metaplasia. (17065012)	Andrieux J.... Demory J.L.	2006	HMGA2
27	High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. (16418333)	Popat U.... Prchal J.T.	2006	JAK2
28	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG fo r Myelofibrosis Research and Treatment (IWG-MRT). (16675707)	Tefferi A.... Kantarjian H.	2006	JAK2
29	FLT3/D835 mutation and inversion of chromosome 16 in leukemic transformation of myelofibrosis. (16962953)	Colovic M.... Colovic N.	2006	TNF
30	Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy. (16532437)	Tefferi A.... Dewald G.W.	2006	EPO
31	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (15837627)	Levine R.L.... Gilliland D.G.	2005	JAK2
32	Case of intraspinal epidural tumor developing after systemic mastocytosis with marked osteosclerosis and myelofibrosis (16440779)	Ohnishi K.... Kohgo Y.	2005	IFNA2
33	Modern management of myelofibrosis. (15725078)	Cervantes F.	2005	VEGFA, EPO
34	Idiopathic myelofibrosis. (16210038)	Barosi G.... Hoffman R.	2005	EPO
35	Involvement of transforming growth factor-beta and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis. (16034467)	Akiyama T.... Niitsu Y.	2005	TGFB1, THPO, BMP6
36	Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia. (16029451)	Dingli D.... Tefferi A.	2005	FKBP5
37	Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis. (15693801)	Benetatos L.... Konstantinos B.L.	2005	EPO
38	Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. (15521916)	Cervantes F.... Montserrat E.	2004	EPO
39	Constitutive expression of the FK506 binding protein 51 (FKBP51) in bone marrow cells and megakaryocytes derived from idiopathic myelofibrosis and non-neoplastic haematopoiesis. (15089760)	Bock O.... Kreipe H.	2004	FKBP5
40	Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents. (12886259)	Visani G.... Piccaluga P.P.	2003	EPO
41	Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression. (12842707)	Komura E.... Giraudier S.	2003	STAT5A, FKBP5
42	Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera. (12270061)	Jensen M.K.... Hasselbalch H.C.	2002	PLAUR, THBD
43	Elevated vascular endothelial growth factor (VEGF) se rum levels in idiopathic myelofibrosis. (11417486)	Di Raimondo F.... Giustolisi R.	2001	VEGFA
44	Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. (9864154)	Taksin A.L.... Debili N.	1999	MPL
45	The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. (9432016)	Yanagida M.... Tokiwa T.	1997	TGFB1, BMP6
46	Combining interferon-alpha2b (IFN) and intravenous immunoglobulins IgG, IgM and IgA (IVIG) in rapid progressive myelofibrosis (MF) with Trisomy 1. (9092696)	Rewald E.... de las Mercedes Francischetti .	1997	CD40LG, CD79A, IFNA1
47	Leukemogenic risk of hydroxyurea therapy in polycythe mia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (8638610)	Nand S.... Fisher S.G.	1996	IFNA1
48	Transformation of aplastic anemia to acute myeloid leukemia with myelofibrosis following treatment with granulocyte colony-stimulating factor and erythropoietin (8779784)	Tsurumi H.... Muto Y.	1996	EPO, EPX
49	Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis. (8285020)	Mohr B.... Huhn D.	1993	EPO
50	Beta-thromboglobulin and platelet factor 4 in a follow-up of acute myelofibrosis (megakaryoblastic leukemia) (2146451)	Palomera Bernal L.... GarcA-a DA-ez I.	1990	PF4

Genes related to myelofibrosis according to GeneCards:

(show top 50)    (show all 106)

id	Symbol	Description	Score	GeneCards Section Context
1	JAK2	Janus kinase 2	11.0	Publications
2	MPL	myeloproliferative leukemia virus oncogene	11.0	Publications
3	THPO	thrombopoietin	11.0	Publications
4	EPO	erythropoietin	11.0	Publications
5	GATA1	GATA binding protein 1 (globin transcription factor 1)	11.0	Publications
6	BMP6	bone morphogenetic protein 6	11.0	Publications
7	FGF2	fibroblast growth factor 2 (basic)	11.0	Publications
8	KIT	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog	11.0	Publications
9	IL3	interleukin 3 (colony-stimulating factor, multiple)	11.0	Publications
10	BMP8B	bone morphogenetic protein 8b	11.0
11	CD177	CD177 molecule	11.0	Publications
12	FKBP5	FK506 binding protein 5	11.0	Publications
13	STAT5A	signal transducer and activator of transcription 5A	11.0	Publications
14	AHSG	alpha-2-HS-glycoprotein	11.0
15	PF4	platelet factor 4	11.0	Publications
16	HMGA2	high mobility group AT-hook 2	11.0	Publications
17	IFNA2	interferon, alpha 2	11.0	Publications
18	FLT3	fms-related tyrosine kinase 3	11.0	Publications
19	IL11	interleukin 11	11.0
20	STAT5B	signal transducer and activator of transcription 5B	11.0
21	TNFRSF11B	tumor necrosis factor receptor superfamily, member 11b	11.0	Publications
22	TIMP2	TIMP metallopeptidase inhibitor 2	11.0
23	FN1	fibronectin 1	11.0
24	LIF	leukemia inhibitory factor	11.0
25	BCR	breakpoint cluster region	11.0	Publications
26	IFNA1	interferon, alpha 1	11.0	Publications
27	CXCL12	chemokine (C-X-C motif) ligand 12	11.0	Publications
28	TGFB1	transforming growth factor, beta 1	11.0	Publications
29	TIMP1	TIMP metallopeptidase inhibitor 1	11.0
30	F8	coagulation factor VIII, procoagulant component	11.0
31	CSF3	colony stimulating factor 3 (granulocyte)	11.0	Publications
32	CEACAM8	carcinoembryonic antigen-related cell adhesion molecule 8	11.0	Publications
33	MCAM	melanoma cell adhesion molecule	11.0	Publications
34	RPN1	ribophorin I	11.0	Publications
35	MKS1	Meckel syndrome, type 1	11.0
36	PRG2	proteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein)	11.0	Publications
37	CEACAM6	carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen)	11.0	Publications
38	NOG	noggin	11.0	Publications
39	TET2	tet methylcytosine dioxygenase 2	11.0	Publications
40	IDH1	isocitrate dehydrogenase 1 (NADP+), soluble	11.0	Publications
41	IDH2	isocitrate dehydrogenase 2 (NADP+), mitochondrial	11.0	Publications
42	ACP5	acid phosphatase 5, tartrate resistant	11.0	Publications
43	DPM1	dolichyl-phosphate mannosyltransferase polypeptide 1, catalytic subunit	11.0
44	BNIP3	BCL2/adenovirus E1B 19kDa interacting protein 3	11.0	Publications
45	EPX	eosinophil peroxidase	11.0	Publications
46	C1S	complement component 1, s subcomponent	11.0	Publications
47	SOCS3	suppressor of cytokine signaling 3	11.0	Publications
48	ZMYM2	zinc finger, MYM-type 2	11.0	Publications
49	MMP8	matrix metallopeptidase 8 (neutrophil collagenase)	11.0	Publications
50	ZFPM1	zinc finger protein, multitype 1	11.0	Publications

Pathways related to myelofibrosis according to GeneDecks:

(show top 50)    (show all 174)

id	Pathway	Score	Top Affiliating Genes
1	Actin-Based Motility by Rho Family GTPases36	10.1	BMP1, THPO, ITGAM, BMP7
2	Ras Pathway36	9.9	BMP7, BMP2, BMP1, KIT, CSF1R, CXCL12
3	IL-6 Pathway36	9.7	IL8, IL3, IL11, BMP7, BMP6, BMP2
4	Endothelin-1 Signaling Pathway36	9.6	CSF3, CSF1R, CXCL12, PDGFRB, PDGFRA, PF4
5	Rac1 Pathway36	9.4	CXCL12, TGFB1, THPO, TIMP2, TIMP1, PDGFRB
6	eIF2 Pathway36	9.4	CXCL12, TIMP2, TIMP1, PDGFRB, PDGFRA, IL3
7	ERK5 Signaling36	9.2	THPO, PDGFRB, PDGFRA, IL3, FGFR1, KDR
8	Jak-STAT signaling pathway20	9.2	TPO, IFNG, IFNA2, IFNA1, IL3, IL15
9	eNOS Signaling36	9.1	TIMP2, TIMP1, PDGFRB, PDGFRA, IL3, FGFR1
10	ERK Signaling36	9.1	TIMP1, KIT, KITLG, PDGFRB, PDGFRA, PF4
11	Paxillin Interactions36	9.1	KDR, BMP2, BMP1, KITLG, KIT, ITGAM
12	Nanog in Mammalian ESC Pluripotency36	9.1	TIMP1, PDGFRB, PDGFRA, IL3, FGFR1, FGF2
13	DHA Signaling36	8.9	TIMP1, PDGFRB, PDGFRA, IL3, FGFR1, FGF2
14	GPCR Pathway36	8.9	CSF1R, CXCL12, BMP6, BMP2, BMP1, KITLG
15	Renin-Angiotensin Pathway36	8.9	CXCL12, BMP2, BMP1, KITLG, KIT, BMP6
16	Tyrosine Kinases / Adaptors3	8.9	LYN, NPM1, CSF1R, SOCS3, TYK2, PDGFRB
17	p70S6K Signaling36	8.9	LYN, CXCL12, TGFB1, THPO, TIMP2, TIMP1
18	ILK Signaling36	8.8	PDGFRB, PDGFRA, IL3, FGFR1, FGF2, FLT3
19	MIF Regulation of Innate Immune Cells36	8.8	CSF3, CXCL12, PF4, TNFSF11, TNF, IL8
20	TGF-Beta Pathway36	8.8	BMP1, KITLG, TGFB1, THPO, TIMP2, TIMP1
21	Nuclear Receptor Activation by Vitamin-A36	8.7	EP300, CXCL12, TGFB1, THPO, TIMP2, TIMP1
22	p53 Mediated Apoptosis36	8.7	TP53, IL3, FGFR1, FGF2, KDR, BMP7
23	Telomerase Components in Cell Signaling36	8.7	CXCL12, KIT, KITLG, BMP1, THPO, TIMP2
24	Hematopoietic cell lineage20	8.7	KIT, KITLG, CD34, ITGAM, CSF3, CSF1R
25	Mitochondrial Apoptosis36	8.7	KDR, BMP7, BMP6, BMP2, BMP1, KITLG
26	NF-KappaB Family Pathway36	8.6	EP300, LYN, CXCL12, TGFB1, THPO, TIMP2
27	PTEN Pathway36	8.6	BMP1, KITLG, KIT, BMP2, BMP7, PRG2
28	14-3-3 Induced Intracellular Signaling36	8.6	FLT3, BMP7, BMP2, BMP1, KITLG, FGF2
29	Activation of PKA through GPCR36	8.5	KIT, KITLG, PTPRC, TIMP1, CXCL12, TGFB1
30	NFAT in Immune Response36	8.5	LYN, CSF1R, CXCL12, TGFB1, KITLG, KIT
31	JNK Pathway36	8.5	CSF1R, CXCL12, TGFB1, THPO, PDGFRB, PDGFRA
32	PPAR Pathway36	8.5	EP300, CXCL12, THPO, TIMP2, PDGFRB, PDGFRA
33	Estrogen Pathway36	8.4	EP300, HDAC9, CSF1R, CXCL12, TGFB1, THPO
34	Intracellular Calcium Signaling36	8.4	EP300, BMP6, BMP2, BMP1, KITLG, KIT
35	Pancreatic Adenocarcinoma36	8.0	TIMP1, BMP1, KITLG, KIT, BMP2, BMP6
36	Akt Signaling36	7.9	CXCR4, BMP7, BMP2, BMP1, KIT, BMPR1B
37	Pathways in cancer20	7.7	EP300, RUNX1, PML, CSF1R, STAT5A, STAT3
38	Phospholipase-C Pathway36	7.7	EP300, HDAC9, LYN, CXCL12, PRG2, TGFB1
39	Apoptotic Pathways in Synovial Fibroblasts36	7.7	CXCL12, TGFB1, THPO, TIMP2, TIMP1, PDGFRB
40	STAT3 Pathway36	7.7	CXCR4, CXCL12, STAT3, TYK2, PF4, TNFSF11
41	Cellular Apoptosis Pathway36	7.6	CXCL12, BMP1, KITLG, KIT, BMP2, BMP6
42	Molecular Mechanisms of Cancer36	7.4	PRG2, JAK1, KDR, LIF, RARB, BMPR1B
43	MAPK Signaling36	7.3	STAT5B, KDR, BMP7, BMP6, BMP2, BMP1
44	PAK Pathway36	7.2	PDGFRA, PF4, TNFSF11, TNF, IL8, IL3
45	Tec Kinases Signaling36	7.0	IL3, IL15, IL11, FGFR1, FGF2, ITGAM
46	Rho Family GTPases36	7.0	FLT3, FN1, ITGAM, KDR, LIF, BMP7
47	JAK-STAT Pathway36	6.9	STAT5A, FGFR1, FGF2, FLT3, JAK2, JAK1
48	Antioxidant Action of Vitamin-C36	6.9	IL15, IL11, FGFR1, FGF2, JAK2, KDR
49	p38 Signaling36	6.1	IL11, FGFR1, FGF2, FLT3, KDR, LIF
50	Cytokine-cytokine receptor interaction20	5.6	EPO, CSF3, CSF1R, CXCR4, CXCR2, CXCR1

Compounds related to myelofibrosis according to GeneDecks:

(show top 50)    (show all 349)

id	Compound	Score	Top Affiliating Genes
1	cyclophosphamide32 34 9 9	13.9	F8
2	threonine32	10.2	BMP2, BMPR1B, MPL, FLT3, FGFR1, WT1
3	gp 13032	10.1	KIT, BMP6, LIF, BCR, MPL, JAK1
4	methylcellulose32	10.1	KIT, KITLG, MYB, BMP2, LIF, CD34
5	filgrastim32 9 9	11.9	KITLG, LIF, ITGAM, IL11, IL3, IFNA2
6	pge232	9.8	BMP2, BMP7, LIF, MMP13, MMP8, FN1
7	aspartate32	9.4	BMP1, BMP6, CD40LG, IL11, F8, TPO
8	su541632	9.0	KIT, KITLG, VEGFA, KDR, FLT3, FGFR1
9	aspirin32 34 18	11.0	KITLG, BMP6, MPL, JAK2, CD79A, CD40LG
10	hydroxyurea32 9 9	10.9	KIT, KITLG, JAK2, MMP8, IL3, IFNA1
11	phosphotyrosine32	8.8	SH2B3, KIT, KDR, BCR, JAK2, MMP14
12	hyaluronic acid32 18	9.8	BMP6, MMP13, FN1, FGF2, IL11, ENG
13	azathioprine32 34 9 9	11.6	BMP2, RARB, LIF, CD79A, IL11, IFNA2
14	cytarabine32 34 9 9	11.6	KIT, KITLG, LIF, BCR, MPO, FLT3
15	doxorubicin32 34 9 9	11.5	KIT, KITLG, MYB, BMP6, KDR, CD40LG
16	agar32	8.5	KITLG, RARB, JAK2, CD40LG, CD34, MMP14
17	rapamycin32 42	9.5	KIT, KITLG, VEGFA, MYB, BMP2, KDR
18	histamine32 18	9.5	KIT, KITLG, BMP6, MPO, CD79A, CD40LG
19	polysaccharide32	8.2	KITLG, BMP2, BMP6, LIF, KDR, CD79A
20	tamoxifen32 34 9 9	11.1	VEGFA, BMP6, KDR, IL3, IFI27, IFNA1
21	ribonucleic acid32	8.1	KIT, KITLG, BMP2, BMP6, BMP7, RARB
22	creatinine32	8.0	KITLG, BMP2, BMP6, BMP7, LIF, MPO
23	progesterone32 42 9 18 9	12.0	KIT, MYB, BMP2, BMP7, RARB, LIF
24	n acetylcysteine32	7.8	KDR, JAK1, JAK2, CD79A, ITGAM, IL3
25	paclitaxel32 34 9 9	10.7	KIT, KITLG, VEGFA, BNIP3, BMP6, LIF
26	zinc32 18	8.6	MYB, BMP1, RARB, ZMYM2, ZFPM1, MPL
27	retinoid32	7.6	MYB, BMP2, BMP6, RARB, ITGAM, MMP13
28	gm-csf32	7.6	KITLG, VEGFA, BMP6, LIF, IL11, IL15
29	ly29400232	7.4	VEGFA, BCR, ITGAM, MMP14, FN1, FGF2
30	indomethacin32 9 9	9.3	BMP2, BMP6, KDR, MPO, JAK2, CD79A
31	testosterone32 9 18 9	10.2	KIT, KITLG, BMP2, RARB, LIF, CD79A
32	matrigel32	7.2	VEGFA, BMP2, BMP6, LIF, KDR, JAK2
33	superoxide32 18	8.2	KITLG, LIF, MPO, ITGAM, MMP14, MMP8
34	5fluorouracil32	7.2	KIT, KITLG, VEGFA, BNIP3, LIF, KDR
35	rantes32	7.1	KITLG, BMP6, LIF, CD40LG, ITGAM, MMP13
36	tgf beta132	6.9	KITLG, BMP6, BMP7, LIF, KDR, MMP13
37	curcumin32	6.6	VEGFA, JAK1, JAK2, MMP13, MMP14, IL15
38	pd 98,05932	6.6	KIT, KITLG, BMP2, BMP6, LIF, BCR
39	cisplatin32 34 9 9	9.6	KITLG, VEGFA, BMP6, RARB, LIF, KDR
40	lactate32	6.3	KIT, KITLG, BNIP3, BMP2, BMP6, LIF
41	phosphatidylinositol32	6.2	SH2B3, KIT, KITLG, BNIP3, BMP6, LIF
42	cysteine32	6.1	MYB, RARB, LIF, KDR, MPL, CD79A
43	paraffin32	6.1	KIT, KITLG, VEGFA, LIF, KDR, CEACAM6
44	actinomycin d32	5.3	KIT, KITLG, VEGFA, MYB, BMP2, RARB
45	vegf32	5.1	KIT, KITLG, BNIP3, BMP2, BMP7, LIF
46	nitric oxide32 9 18 9	7.6	KIT, KITLG, BNIP3, BMP2, BMP6, LIF
47	cycloheximide32	4.5	KIT, KITLG, VEGFA, MYB, BMP2, BMP6
48	dexamethasone32 42 34 9 9	7.8	KITLG, VEGFA, MYB, BMP2, BMP6, BMP7
49	serine32	3.2	KIT, KITLG, MYB, BMP1, BMP2, BMP6
50	tyrosine32	3.2	SH2B3, KIT, KITLG, VEGFA, MYB, BMP2

Cellular components related to myelofibrosis according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	platelet alpha granule lumen	GO:031093	9.8	TGFB1, THBS1, TIMP1, PF4, F8, FN1
2	cell surface	GO:009986	8.0	CSF1R, CXCR4, CXCR2, TGFB1, THBD, TIMP2
3	external side of plasma membrane	GO:009897	7.4	TNF, PTPRC, THBS1, TGFBR2, CXCL12, CXCR4
4	extracellular region	GO:005576	7.0	PF4, NOG, PLAUR, PTH, TNFSF11, TNFRSF11B
5	integral to plasma membrane	GO:005887	6.4	TNF, TNFSF11, PTPRC, PLAUR, PDGFRA, PDGFRB
6	extracellular space	GO:005615	6.3	EPO, ENG, IFNA2, IFNG, F8, TNF
7	cytoplasm	GO:005737	5.3	TYK2, KRT7, WT1, PDGFRB, PDGFRA, TNFSF11

Biological processes related to myelofibrosis according to GeneDecks:

(show top 50)    (show all 99)

id	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of tyrosine phosphorylation of Stat3 protein	GO:042517	10.5	IL15, CSF1R, JAK2, LIF, KIT
2	extracellular matrix disassembly	GO:022617	10.5	MMP13, MMP14, TIMP2, TIMP1, ENG, MMP8
3	JAK-STAT cascade	GO:007259	10.5	STAT5B, STAT5A, STAT3, SOCS3, JAK2
4	JAK-STAT cascade involved in growth hormone signaling pathway	GO:060397	10.4	JAK2, STAT3, STAT5A, STAT5B, SOCS3, LYN
5	positive regulation of pathway-restricted SMAD protein phosphorylation	GO:010862	10.4	ENG, BMP2, BMP7, TGFB1, BMP6
6	positive regulation of bone mineralization	GO:030501	10.4	TGFB1, BMP2, BMP6, BMP7, BMPR1B, PTH
7	epithelial to mesenchymal transition	GO:001837	10.3	HMGA2, BMP2, BMP7, NOG, TGFB1
8	erythrocyte differentiation	GO:030218	10.3	ZFPM1, GATA1, LYN, JAK2, KIT
9	cartilage development	GO:051216	10.3	BMP2, BMP6, BMP7, BMP8B, NOG, TGFBR2
10	acute-phase response	GO:006953	10.3	F8, FN1, STAT3, STAT5B, AHSG
11	BMP signaling pathway	GO:030509	10.2	NOG, BMP2, BMP6, BMP7, BMPR1B, ENG
12	positive regulation of MAPK cascade	GO:043410	10.2	FGFR1, KIT, KDR, FLT3, IL11, PTPRC
13	mesenchymal cell differentiation	GO:048762	10.1	FGFR1, BMP7, BMP2, PLAUR, HMGA2
14	platelet degranulation	GO:002576	10.0	TIMP1, F8, PF4, FN1, VEGFA, TGFB1
15	hemopoiesis	GO:030097	10.0	KITLG, FLT3, CSF1R, CD34, RUNX1, KIT
16	positive regulation of phospholipase C activity	GO:010863	10.0	FGF2, PDGFRB, PDGFRA, FGFR1, KIT
17	positive regulation of mast cell proliferation	GO:070668	10.0	STAT5A, LYN, KITLG
18	positive regulation of phosphatidylinositol 3-kinase activity	GO:043552	10.0	LYN, TGFB1, PDGFRB, FGF2, FLT3, KIT
19	positive regulation of endothelial cell proliferation	GO:001938	9.9	FGF2, VEGFA, BMP2, BMP6, KDR, CXCL12
20	platelet activation	GO:030168	9.9	TIMP1, PF4, F8, THBS1, FN1, LYN
21	positive regulation of gene expression	GO:010628	9.9	CD34, VEGFA, HMGA2, KIT, PLAUR, PF4
22	skeletal system development	GO:001501	9.8	BMP8B, BMPR1B, AHSG, PTH, NOG, TNFRSF11B
23	immune response	GO:006955	9.8	LIF, TNFSF11, IL3, IL15, BMP6, CSF3
24	positive regulation of phosphatidylinositol 3-kinase cascade	GO:014068	9.8	KIT, KDR, FLT3, JAK2, FGFR1, PDGFRA
25	pathway-restricted SMAD protein phosphorylation	GO:060389	9.8	BMP2, BMP7, TGFB1, TGFBR2
26	embryonic hemopoiesis	GO:035162	9.7	TPO, SH2B3, KIT, GATA1, RUNX1, TGFBR2
27	positive regulation of neuron differentiation	GO:045666	9.7	EPO, CXCL12, FGFR1, IFNG, BMP6, BMP2
28	positive regulation of peptidyl-tyrosine phosphorylation	GO:050731	9.7	IL11, LIF, GATA1, IL3, JAK2, KITLG
29	B cell differentiation	GO:030183	9.6	HDAC9, PTPRC, IL11, FLT3, CD40LG, CD79A
30	extracellular matrix organization	GO:030198	9.4	BMP1, TIMP2, MMP13, MMP14, MMP8, TNF
31	protein autophosphorylation	GO:046777	9.4	LYN, CSF1R, PDGFRB, KDR, PDGFRA, JAK2
32	cytokine-mediated signaling pathway	GO:019221	9.4	PML, PF4, TYK2, STAT3, STAT5A, STAT5B
33	peptidyl-tyrosine phosphorylation	GO:018108	9.4	LYN, CSF1R, STAT5A, PDGFRB, KIT, KDR
34	positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway	GO:038091	9.3	VEGFA, PDGFRA, PDGFRB
35	positive regulation of protein phosphorylation	GO:001934	9.1	VEGFA, BMP2, ENG, EP300, TNF, CSF1R
36	positive regulation of cell migration	GO:030335	8.9	TGFB1, CSF1R, LYN, KDR, BMP2, PDGFRB
37	positive regulation of ERK1 and ERK2 cascade	GO:070374	8.8	PDGFRA, FGF2, CSF1R, TNF, KDR, PDGFRB
38	blood coagulation	GO:007596	8.8	FN1, SH2B3, VEGFA, LYN, GATA1, THPO
39	positive regulation of MAP kinase activity	GO:043406	8.7	TNFSF11, TGFB1, PDGFRB, KITLG, TNF, FGFR1
40	response to hypoxia	GO:001666	8.7	VEGFA, SOCS3, CXCR4, CXCL12, TGFB1, THBS1
41	positive regulation of cell proliferation	GO:008284	8.6	KIT, PDGFRA, PDGFRB, TIMP1, THPO, CSF1R
42	virus-host interaction	GO:019048	8.5	TGFB1, BNIP3, PDGFRA, STAT3, KDR, TP53
43	signal transduction	GO:007165	8.3	STAT3, PDGFRB, PLAUR, NPM1, TNFRSF11B, IL8
44	negative regulation of transcription, DNA-dependent	GO:045892	8.3	WT1, MYB, HDAC9, PML, TGFB1, TNF
45	response to drug	GO:042493	8.2	STAT3, TGFBR2, TGFB1, LYN, EP300, SOCS3
46	negative regulation of apoptotic process	GO:043066	8.1	NOG, PLAUR, TNF, TP53, HMGA2, TIMP1
47	negative regulation of cell proliferation	GO:008285	8.1	BMP2, PML, TNF, GATA1, LYN, NPM1
48	inflammatory response	GO:006954	7.9	HDAC9, CSF1R, CXCR4, CXCR2, CXCR1, KIT
49	positive regulation of transcription from RNA polymerase II promoter	GO:045944	7.0	BMP6, IFNG, ENG, MYB, IL11, FGF2
50	negative regulation of transcription from RNA polymerase II promoter	GO:000122	6.9	STAT3, NOG, RARB, ASXL1, FGFR1, IFNG

Molecular functions related to myelofibrosis according to GeneDecks:

(show all 16)

id	Name	GO ID	Score	Top Affiliating Genes
1	growth hormone receptor binding	GO:005131	10.4	TYK2, JAK2, JAK1
2	SMAD binding	GO:046332	10.1	BMP2, BMPR1B, HMGA2, TGFBR2, PML
3	glucocorticoid receptor binding	GO:035259	10.0	EP300, STAT5B, STAT3
4	transmembrane receptor protein tyrosine kinase activity	GO:004714	9.9	KIT, KDR, FLT3, PDGFRA
5	vascular endothelial growth factor-activated receptor activity	GO:005021	9.8	PDGFRB, PDGFRA, FLT3, KDR
6	vascular endothelial growth factor binding	GO:038085	9.8	KDR, PDGFRA, PDGFRB
7	receptor signaling protein tyrosine kinase activity	GO:004716	9.7	LYN, KDR, KIT
8	growth factor activity	GO:008083	9.7	CXCL12, TGFB1, THPO, IL3, IL11, FGF2
9	heparin binding	GO:008201	9.6	PRG2, THBS1, PF4, PTPRC, FGFR1, FGF2
10	protein tyrosine kinase activity	GO:004713	9.5	LYN, TYK2, PDGFRB, FGFR1, JAK2, JAK1
11	platelet-derived growth factor receptor binding	GO:005161	9.4	LYN, PDGFRB, PDGFRA, VEGFA
12	protein heterodimerization activity	GO:046982	8.8	RUNX1, NPM1, PML, TGFB1, TP53, BMP6
13	protein homodimerization activity	GO:042803	8.7	PDGFRA, TGFB1, CSF1R, PML, NPM1, RUNX1
14	transcription factor binding	GO:008134	8.6	EP300, HDAC9, RUNX1, STAT3, TP53, HMGA2
15	cytokine activity	GO:005125	7.8	KITLG, IL3, IFNA2, IFNG, TNF, TNFRSF11B
16	protein binding	GO:005515	2.3	STAT5A, STAT5B, CXCR4, PML, NPM1, RUNX1